Toronto Dominion Bank Has $7.16 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Toronto Dominion Bank lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 67,800 shares of the medical equipment provider’s stock after selling 947 shares during the quarter. Toronto Dominion Bank’s holdings in Zimmer Biomet were worth $7,162,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ZBH. Dorsey & Whitney Trust CO LLC lifted its stake in Zimmer Biomet by 2.3% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock valued at $485,000 after purchasing an additional 102 shares during the last quarter. M&T Bank Corp raised its position in shares of Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock valued at $2,834,000 after buying an additional 108 shares in the last quarter. MGO One Seven LLC raised its position in shares of Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 110 shares in the last quarter. FWG Holdings LLC increased its stake in Zimmer Biomet by 3.5% in the fourth quarter. FWG Holdings LLC now owns 3,715 shares of the medical equipment provider’s stock valued at $402,000 after acquiring an additional 124 shares during the last quarter. Finally, Erste Asset Management GmbH increased its stake in Zimmer Biomet by 0.3% in the fourth quarter. Erste Asset Management GmbH now owns 41,487 shares of the medical equipment provider’s stock valued at $4,434,000 after acquiring an additional 124 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ZBH shares. Royal Bank of Canada decreased their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company dropped their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group dropped their price objective on shares of Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating on the stock in a report on Tuesday, May 6th. Raymond James lowered their target price on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $111.53.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Stock Performance

ZBH opened at $93.28 on Friday. The stock has a market capitalization of $18.46 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.95 and a beta of 0.78. The company has a fifty day moving average of $100.36 and a 200 day moving average of $104.92. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $116.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same quarter last year, the business earned $1.94 earnings per share. Zimmer Biomet’s quarterly revenue was up 1.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.